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Abstract
The anti-apoptotic protein Bcl-2 is a well-known and attractive therapeutic target for cancer. In the present study the
solution-phase T3P-DMSO mediated efficient synthesis of 2-amino-chromene-3-carbonitriles from alcohols, malanonitrile
and phenols is reported. These novel 2-amino-chromene-3-carbonitriles showed cytotoxicity in human acute myeloid
leukemia (AML) cell lines. Compound 4g was found to be the most bioactive, decreasing growth and increasing apoptosis
of AML cells. Moreover, compound 4g (at a concentration of 5 mM) increased the G2/M and sub-G1 (apoptosis) phases of
AML cells. The AML cells treated with compound 4g exhibited decreased levels of Bcl-2 and increased levels of caspase-9. In
silico molecular interaction analysis showed that compound 4g shared a similar global binding motif with navitoclax
(another small molecule that binds Bcl-2), however compound 4g occupies a smaller volume within the P2 hot spot of Bcl-2.
The intermolecular p-stacking interaction, direct electrostatic interactions, and docking energy predicted for 4g in complex
with Bcl-2 suggest a strong affinity of the complex, rendering 4g as a promising Bcl-2 inhibitor for evaluation as a new
anticancer agent.
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Introduction
Programmed cell death, or apoptosis, is the primary mechanism
for the removal of aged and damaged cells. Cancer cells can gain a
growth advantage over their normal counterpart by either dividing
more quickly, not undergoing terminal differentiation and thus
remaining in the proliferative pool, or not undergoing apoptosis
[1]. On the functional level, interactions between pro-apoptotic
proteins such as Bax, Bak, Bad, Bim, Noxa, Puma, and pro-
survival proteins such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1
control the regulation of programmed cell death. Cancer cells alter
the balance among these opposing factions to undermine normal
apoptosis, and thus gain a survival advantage [2,3]. The first
identified apoptotic regulator, Bcl-2, was cloned from human
follicular B cell lymphoma cells which nearly invariably have a
chromosomal t(14;18) translocation, placing the Bcl-2 gene under
the control of the powerful IgG heavy chain promoter [4,5] with
the consequence of elevated levels of Bcl-2 promoting increased
cell survival [6]. A common feature in many human tumors is
overexpression of the pro-survival Bcl-2 family members Bcl-2 and
Bcl-xL, which make tumor cells resistant to conventional cancer
therapeutic agents.
Numerous synthetic small molecules targeting Bcl-2 protein have
been studied extensively and few of them have advanced to clinical
trials (Figure 1). Structure-based drug design approaches have
previously yielded small molecules that bind to Bcl-2 such as
navitoclax (ABT-263) [7]. This molecule binds to Bcl-2 and Bcl-xL;
unfortunately in clinical trials it caused severe thrombocytopenia
due to binding and inhibiting Bcl-xL [8]. Another structure-based
synthesis has produced BM-957, a potent small-molecule inhibitor
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of Bcl-2 and Bcl-xL, which was capable of achieving complete
tumor regression in a small lung cancer xenograft model [9].
Similarly, the co-crystal structure of Bcl-2 resulted in identification
of a small molecule called ABT-199; a Bcl-2–selective inhibitor
approved by the FDA for cancer therapy [10]. The above study
strongly suggested that an indole based carbinol inhibited the
growth of prostate cancer cells by arresting them in the G1 phase of
the cell cycle, leading to apoptosis via down-regulation of Bcl-2.
Figure 1. Known small molecules that target Bcl-2. As can be seen, different bioactive scaffolds have been established, however both efficacy
and avoiding off-target effects of this class of compounds still remains a challenge.
doi:10.1371/journal.pone.0107118.g001
Figure 2. Molecular diversity of amino-nitrils. Structural representation (ball and stick model) of the combinatorial libraries of Bcl-2 inhibitors
that depicts top and bottom row side chains, which are incorporate to three amino nitrile scaffolds.
doi:10.1371/journal.pone.0107118.g002
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Chromene-based natural and synthetic compounds have
contributed substantially to the development of therapeutics as
anti-neoplastic agents against various human malignancies
[11,12]. Sesilin, tephrosin, calanone and acronycine are some of
the naturally occurring chromene derivatives with a very good
anti-cancer activity. An important breakthrough in the develop-
ment of 4H-chromenes as anti-cancer agents was given by the
discovery of HA 14-1, which targets the Bcl-2 protein. It is
reported to inhibit Bcl-2 by abrogating the interaction of Bax/Bcl-
2, and it has also shown synergistic effect when combined with
flavopiridol [13–15]. Therefore, the design of new chromene
derivatives against anti-apoptotic members of the Bcl-2 family
provides a plausible target in cancer therapeutics [16]. We recently
reported the synthesis and explored the biological property of
chromene-containing benzoxazines and other biologically impor-
tant heterocyclic libraries [17,18].
In order to improve the efficacy of chromene-based small
molecules as selective inhibitors of Bcl-2, we have in the current
work synthesized a library of 2-amino chromene-3-carbonitriles to
quantify and compare the molecular diversity between different
types of libraries that would interact with Bcl-2 (Figure 2). We
also outline the simple graphical approach for describing and
comparing molecular diversity within the library of amino-nitriles.
Materials and Methods
Synthesis and characterization of various 2-amino-chromene-
nitriles were provided as supplementary data (Data S1 and Table
S1)
Figure 3. Synthesis of a library of 2-amino-chromene-3-
carbonitriles from alcohols.
doi:10.1371/journal.pone.0107118.g003
Figure 4. Plausible mechanism of the T3P-DMSO mediated synthesis of title compounds.
doi:10.1371/journal.pone.0107118.g004
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Table 1. Physical characteristics of the synthesized 2-amino-chromene-3-carbonitriles.
Entry 1 (Alcohol) 3 (Phenols) Title compounds (4a-t) Time (Hr) Yield (%) MP (OC)
4a (3-nitrophenyl)methanol naphthalen-2-ol 2-amino-4-(3-nitrophenyl)-4H-
benzo[g]chromene-3-carbonitrile
3–4 95a 179 –182
4b (4-bromophenyl)methanol naphthalen-2-ol 2-amino-4-(4-bromophenyl)-4H-
benzo[g]chromene-3-carbonitrile
4.5 96a 138–140
4c (1H-indol-3-yl)methanol naphthalen-2-ol 2-amino-4-(1H-indol-3-yl)-4H-
benzo[g]chromene-3-carbonitrile
5 92a 198–200
4d 3-(hydroxymethyl)-4H-chromen-4-one naphthalen-2-ol 2-amino-4-(4-oxo-4H-chromen-3-yl)
-4H-benzo[g]chromene-3-carbonitrile
9 84 -
4e (2-butyl-4-chloro-1H-imidazol-5-yl)methanol naphthalen-2-ol 2-amino-4-(2-butyl-4-chloro-1H-
imidazol-5-yl)-4H-benzo[g]chromene
-3-carbonitrile
12 79 -
4f (2-nitrophenyl)methanol naphthalen-2-ol 2-amino-4-(2-nitrophenyl)-4H-
benzo[g]chromene-3-carbonitrile
4-5 89a -
4g (2,6-dichlorophenyl)methanol naphthalen-2-ol 2-amino-4-(2,6-dichlorophenyl)-
4H-benzo[g]chromene-3-
carbonitrile
8 91 -
4h (4-fluorophenyl)methanol naphthalen-2-ol 2-amino-4-(4-fluorophenyl)-
4H-benzo[g]chromene-3-
carbonitrile
4.5 93a 187–189
4i (4-fluorophenyl)methanol resorcinol 2-amino-4-(4-fluorophenyl)-7-
hydroxy-4H-chromene-3-
carbonitrile
6 96a 218–220
4j (1H-indol-3-yl)methanol resorcinol 2-amino-7-hydroxy-4-(1H-indol
-3-yl)-4H-chromene-3-carbonitrile
5 92a -
4k 3-(hydroxymethyl)-4H-chromen-4-one resorcinol 29-amino-79-hydroxy-4-oxo-4H,
49H-[3,49-bichromene]-39-
carbonitrile
9.5 82 -
4l (2-butyl-4-chloro-1H-imidazol-5-yl)methanol resorcinol 2-amino-4-(2-butyl-4-chloro-1H-
imidazol-5-yl)-7-hydroxy-4H-
chromene-3-carbonitrile
14 74 -
4m (4-bromophenyl)methanol 4-hydroxy-2H-
chromen-2-one
2-amino-4-(4-bromophenyl)-5-oxo
-4,5-dihydropyrano[3,2-c]chromene
-3-carbonitrile
3.5 97a 254–256
4n (1H-indol-3-yl)methanol 4-hydroxy-2H-
chromen-2-one
2-amino-4-(1H-indol-3-yl)-5-oxo
-4,5-dihydropyrano[3,2-c]
chromene-3-carbonitrile
5.5 86a 215–217
4o 3-(hydroxymethyl)-4H-chromen-4-one 4-hydroxy-2H-
chromen-2-one
2-amino-5-oxo-4-(4-oxo-4H-
chromen-3-yl)-4,5-
dihydropyrano[3,2-c]
chromene-3-carbonitrile
10 72 -
4p (2-butyl-4-chloro-1H-imidazol-5-yl)methanol 4-hydroxy-2H-
chromen-2-one
2-amino-4-(2-butyl-4-chloro-
1H-imidazol-5-yl)-5-oxo-4,5-
dihydropyrano[3,2-c]
chromene-3-carbonitrile
9 81 -
4q (3,4-dimethoxyphenyl)methanol 4-hydroxy-2H-
chromen-2-one
2-amino-4-(3,4-
dimethoxyphenyl)-5-oxo-
4,5-dihydropyrano[3,2-c]
chromene-3-carbonitrile
2.5 82a 228–230
4r (2-methyl-1H-indol-3-yl)methanol 4-hydroxy-2H-
chromen-2-one
2-amino-4-(2-methyl-1H-
indol-3-yl)-5-oxo-4,5-
dihydropyrano[3,2-c]
chromene-3-carbonitrile
6 69 -
4s (3,4-dimethoxyphenyl)methanol 4-hydroxy-6,7-
dimethyl-2H-
chromen-2-one
2-amino-4-(3,4-
dimethoxyphenyl)-8,9-
dimethyl-5-oxo-4,5-
dihydropyrano[3,2-c]
chromene-3-carbonitrile
3.5 84 -
4t (4-(trifluoromethyl)phenyl)methanol 4-hydroxy-6,7-
dimethyl-2H-
chromen-2-one
2-amino-8,9-dimethyl-
5-oxo-4-(4-(trifluoromethyl)
phenyl)-4,5-dihydropyrano
[3,2-c]chromene-3-carbonitrile
4 89 -
a Isolated yield.
MP- Melting point.
doi:10.1371/journal.pone.0107118.t001
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Cell Culture
Myeloid leukemia cell lines; MOLM13 and MV4-11 were kind
gifts by Dr. Martin Grundy (Department of Academic Haematol-
ogy, University of Nottingham) [28]. MOLM14 cells were
generously provided by Dr. Didier Bouscary (Department of
Hematology-Immunology, Institut Cochin, Paris, France) [29].
The HL-60 cell line was purchased from ATCC. Cell lines were
cultured and maintained in RPMI medium containing 10% fetal
bovine serum (FBS), 1% penicillin-streptomycin (Invitrogen,
Carlsbad, CA) at 37uC in a humidified atmosphere with 5%
CO2. All cell lines were regularly screened for absence of
mycoplasma. Bone marrow cells from C57BL/6 mice were
cultured in IMDM supplemented with 20% FBS and cytokines
(10 ng/ml recombinant mouse IL-3, 10 ng/ml recombinant
mouse IL-6 and 50 ng/ml recombinant mouse Stem Cell Factor
(SCF). Antibodies against Bcl-2, Bcl-xL, Cleaved caspase-9 and
GAPDH were purchased from Cell Signalling. ABT-737 was used
as a reference compound for all the experiments.
Cell proliferation assay
Cellular proliferation of AML cell lines was measured by using
methylthiazolyl-diphenyl-tetrazolium bromide (MTT; sigma-al-
drich). 8,000 cells per well were seeded in triplicate, 96-well plates
(Corning, Lowell, MA, USA) in 100 ml of medium having 2-amino-
chromene-nitriles derivatives. Cells were incubated overnight at
37uC in a CO2 incubator. At the end of the culture duration, 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was
added into each well, and the final concentration of MTT in each
well was 0.5 mg/ml. MTT plates were incubated at 37uC in a CO2
incubator for 3 hr. After incubation, Formazan crystals were
dissolved in 100 ml of stop solution (SDS-HCl). Absorbance was
measured at 570 nm using a Tecan Infinite 200 PRO spectropho-
tometer (Mannedorf, Switzerland).
Annexin V and propidium iodide (Annexin V–PI)
apoptosis assays
HL-60, MOLM13, MOLM14 and MV4-11 (16105) cells were
seeded into each well of a 6-well plate and treated with 4g at the
IC50 concentration for 48 and 72 hours. Staining was performed
using FITC Annexin V Apoptosis Detection Kit II, BD
Pharmingen (BD Biosciences, USA) according to the manufactur-
er protocol. Briefly, cells were washed with PBS at least three
times, re-suspended in 16 binding buffer, and FITC-conjugated
annexin V and propidium iodide (PI) was added for 15 min in the
dark. Samples were analyzed by a LSR-II flow cytometer (Becton-
Dickinson, San Jose, CA, USA).
Immunoblot analysis
Cell lysates were prepared using the ProteoJET Mammalian
Cell lysis reagent (Fermentas) and the 16 protease inhibitor
mixture (Roche Molecular Biochemicals, Pleasanton, CA). Immu-
noblotting was performed as described earlier [30]. Monoclonal
antibodies against Bcl-2, GAPDH and cleaved caspase-9 (Cell
Signalling, Boston, MA, USA) were used.
Figure 5. Screening of active compounds affecting the proliferation of HL-60 AML cells from a library of 2-amino-chromene-nitriles
derivatives. MTT assays were performed after incubation of HL-60 cells with indicated concentrations of chromene derivatives 4 (a-y) for 72 hr. For
each concentration, percent inhibition values were calculated and data was normalized to diluent controls. The scale X-axis is non-linear and the data
represent mean 6SD from three independent experiments done in quadruplicates. ** P#0.001 (Student’s t-test).
doi:10.1371/journal.pone.0107118.g005
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In Vitro analysis of the effect of amino-nitriles against
Bcl-2
Zymed Bcl-2 ELISA kit was used for the evaluation of the
binding of small molecules to Bcl-2. Initially various concentra-
tions of small molecules and the human Bcl-2 was incubated for
5 minutes and transferred the mixture to the mAb coated 96-well
plate. The bound Bcl-2 was tagged with anti-Bcl-2 that conjugated
with biotin. The biotin conjugate was bound with streptauvidin-
HRP. The Streptavidin-HRP was reacted with TM and the
absorbance is measured at 450 nm. A standard curve is prepared
to determine the Bcl-2 concentration and% inhibition of the Bcl-2
binding to its antibody was presented.
Molecular docking analysis
The molecular modeling was achieved with commercially
available InsightII, Discovery Studio (DS) Version 2.5 software
packages. Initially, the 3D structure of Bcl-2 was cleaned and the
navitoclax binding site was considered for further analysis. All of
the calculations were performed using the CHARMM force field
as reported previously [31]. Each energy-minimized final docking
position of the individual apigenin structural analogues was
evaluated using the interaction score function in the CDOCKER
module of DS version 2.5 as reported previously from our group
[32]. Based on the low CDOCKER energy value, compound 4g
was selected for further studies.
Results and Discussion
Synthesis of novel 2-amino chromene-3-carbonitriles
derivatives
Naturally occurring 2-amino-carbonitriles containing pyr-
ano[3,2-c]pyridine-based structural motifs are commonly found
in alkaloids and exhibit diverse biological activities, including anti-
cancer activity [19]. A series of pyrano[3,2-c]pyridine based
flavone and coumarin isosteres containing a 2-amino carbonitrile
moiety have also exhibited a broad spectrum of antitumor activity
against breast cancer cells [20]. In continuation of our efforts to
develop efficient solution phase synthesis of novel small molecules
Figure 6. Anti-proliferative effect of 4g tested against AML cell lines in liquid culture. Panels (A–D): MTT assay determined cell viability of
AML cells. 8,000 cells per well were seeded for MOLM13, MOLM14, MV4-11 and HL-60 cells in 96 well plates in quadruplicates. A series of dilutions
(starting from 1.25 mm to 10 mm) of 4g were added into the wells. Cell proliferation was measured after compound 4g treatment relative to diluents
controls. Results represent the mean 6SD of three independent experiments with quadruplicate wells per experiment point. ** P#0.001; *** P#
0.0001 (Student’s t-test).
doi:10.1371/journal.pone.0107118.g006
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with anti-cancer agents, we reported before the synthesis of 2-
amino-chromene-3-carbonitriles [21,22], where solution phase
T3P-DMSO mediated the efficient synthesis using alcohols,
malanonitrile and phenols (Figure 3). The possible mechanism
involves the reaction of DMSO with T3P to give an electrophilic
sulphur species (c), followed by a substitution reaction of alcohol to
form an arylsulphonium salt. This is followed by a hydrogen
abstraction of the arylsulphonium salt by hydrolyzed T3P (d) to
create a carbonyl compound after elimination of dimethyl sulfide.
Next, the phenolic hydroxyl group (2) attacks the carbonyl carbon,
and the oxygen on the carbonyl group attacks one more T3P to
form an intermediate (e), which in turn attacks malanonitrile (3) to
give an anion. This anion attacks intermediate (f), which upon
further cyclization converts to compound 4(a-t) (Figure 4). In
addition, a variety of aromatic and heterocyclic alcohols, b-
naphthol/resorcinol/4-hydroxycoumarin and malanonitrile were
added to T3P (50% solution in ethylacetate), DMSO and ethyl
acetate as a solvent medium, in order to obtain compounds 4a-t.
The reaction between 1, 2 and 3 in the presence of T3P (2.5
equiv) DMSO generally resulted in a product of appreciable yield
(see Table 1) as well as being rather versatile with regard to the
choice of substrates. It was observed during the reaction that an
increase in temperature resulted in the gradual decrease in yield of
the product.
2-amino chromene-3-carbonitrile derivatives elicit an
anti-proliferative effect against AML cells
4H-chromenes are potent cytotoxic agents which have been
tested against a panel of human cancer cell lines, and a chromene
analog, Crolibulin (EPC2407) is currently in Phase I/II clinical
trials for the treatment of advanced solid tumors [23]. We initially
tested a series of 20 chromene derivatives 4(a-t) for their cytotoxic
effects against a human acute myeloid leukemia (AML) cell line
(HL-60), using three different concentrations (10, 50 and 100 mM)
of 2-amino-chromene-carbonitriles. Among the tested compounds,
4g significantly (P#0.001) decreased proliferation of the AML
cells, even at 10 mM concentrations. Other derivatives of these
compounds showed either no or very low effect at 10 mM
concentrations (Figure 5).
Additional studies were performed for compound 4g, which was
the most active among the structurally related compounds tested
in culture. The anti-proliferative activity of compound 4g against
three additional AML cell lines (MOLM13, MOLM14 and MV4-
11) was examined. Again, compound 4g significantly decreased
Figure 7. Expression of Bcl-2 proteins in human AML cell lines and anti-proliferative effect of compound 4g (5, 10 mm against
C57BL/6 mouse bone marrow cells in liquid culture. A
represent the mean6SD of three independent experiments with quadruplicate wells per experiment point. B. MOLM13, MOLM14, MV4-11 and HL-60
AML cells were cultured either with compound 4g (5 mM, 24 hr) or diluents control, and levels of Bcl-2 and Bcl-xL were examined by western blot.
GAPDH was used as an internal loading control.
doi:10.1371/journal.pone.0107118.g007
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. MTT assay determined cell viability of C57BL/6 mouse total bone marrow cells. Results
the proliferation of the AML cells with an ED50 of 5 to 10 mM
after 48, 72 and 96 hours of culture (Figures 6). Compound 4g
inhibited proliferation of the AML cells with an IC50 of 5 mM.
Further, C57BL/6 mouse bone marrow cells were treated with 5,
10 mM compound 4g to assess the effect on normal hematopoietic
cells. As shown in Figure 7A, compound 4g (5, 10 mM) treatment
displayed minimal anti-proliferative response against the normal
bone cells suggesting that compound 4g decreases proliferation of
the AML cells, and has little effect on proliferation of normal bone
marrow cells.
Compound 4g inhibits Bcl-2 protein and triggers cell
cycle arrest at G2/M phase in AML cells
HA14-1 is a cell permeable Bcl-2 inhibitor, and acts by binding
to the surface pocket of Bcl-2 [24] and disrupts the Bax/Bcl-2
interaction, resulting in induction of apoptosis of tumour cells.
Interestingly, treatment of HL-60, MOLM13, MOLM14, MV4-
11 cell lines with compound 4g (5 mM, 24 hr) decreased levels of
Bcl-2 (Figure 7B). Moreover, we checked the effect of compound
4g on the expression of the Bcl-xL. Our western blotting results
showed that compound 4g does not inhibit the expression of Bcl-
xL protein (Figure 7C).
The effect of compound 4g (5 mM, 72 hr) on the cell cycle
analysis of MOLM13, MOLM14, and MV4-11 AML cells using
flow cytometry showed significant increase in the G2/M and sub-
G1 phases (apoptosis), as compared to the diluents control cells
(Figures 8A and 8B). The cell population in the G1 phase of the
cell cycle decreased.
Compound 4g induces apoptosis of AML cells
Core scaffolds such as flavones or chromenes induce apoptosis
in human myeloid tumor cells [25]. Therefore, the HL-60,
MOLM13, MOLM14, and MV4-11 cells were treated with
compound 4g (5 mM for 48 and 72 hr) and analysed for the
induction of apoptosis using FITC-conjugated annexin V (AV)
and propidium iodide (PI). Both early (AV+PI2), as well as, late
(AV+PI+) apoptosis occurred in AML cells (Figure 9A). Detailed
percentage of apoptotic cells in cell lines are summarized in
supplementary data (Table S1). This was associated with
increased levels of cleaved caspase-9 in these cell lines (Fig-
ure 9B), which is an enzyme known to be activated during
programmed cell death.
Figure 8. Cell cycle analysis of AML cell lines treated with compound 4g (5 mM, 72 hr). Panel (A), fluorescent activated cell sorter analyzed
the percent cells in each phase of the cell cycle. Cell cycle analysis of three cell lines (MOLM14, MOLM14 and MV4-11) treated with diluents control
and compound 4g (5 mM) for 72 h. The figures are representative of three independent experiments. Data are presented in histograms as mean6SD
of three independent experiments. * P#0.005; ** P#0.001.
doi:10.1371/journal.pone.0107118.g008
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In Vitro analysis of the effect of amino-nitriles against
Bcl-2
Bcl-2 ELISA kit from Zymed was used to determine the
inhibitory activity of most active of small molecule towards Bcl-2.
Among the four tested compounds, 4a, 4h, and 4f at 30 mM
concentration, inhibited the Bcl-2 binding to its antibody by 37.8,
53.0, 61.9% respectively (Figure 10). The most active compound
4g inhibited the Bcl-2 binding to its antibody effectively with an
IC50 value of 17.8 mM, indicate its strong affinity towards Bcl-2
compared to structurally related chromenes. Among the tested
small molecules, 2,6- dichlorophenyl, 2-nitrophenyl, 4-fluorophe-
nyl and 3-nitrophenyl side chain containing amino-nitrils
displayed significant binding affinity towards Bcl-2 indicating that
electron withdrawing group favors the effective binding to Bcl-2.
In silico docking analysis of chromene based small
molecule (4g) that targets Bcl-2
Bcl-2 appears to be a possible target for compound 4g as it
induced the apoptosis by decreasing the level of anti-apoptotic
protein Bcl-2 in AML cell lines. Hence, we performed in silico
Figure 9. Compound 4g induces apoptosis of AML cells in a time-dependent manner. A. Flow cytometry profile represents Annexin V-FITC
staining on the X-axis and PI staining on the Y-axis. The upper left quadrants display the necrotic cells, upper right quadrants show the late apoptotic
cells, lower left quadrants display the live cells and lower right quadrants show the early apoptotic cells. B. Western blot showed increased expression
of cleaved caspase-9 protein in compound 4g treated AML cells compared to control cells.
doi:10.1371/journal.pone.0107118.g009
Figure 10. Amino-nitriles inhibit Bcl-2 in vitro. Most active small
molecules 4a, 4f, 4g and 4h were analysed for their Bcl-2 inhibitory
activity. 4g displayed higher percentage of Bcl-2 inhibition in a dose
dependent manner and presented as the most potent inhibitor of Bcl-2.
doi:10.1371/journal.pone.0107118.g010
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molecular docking using the three-dimensional structures of Bcl-2,
which consists of two central primarily hydrophobic a-helices
surrounded by amphipathic helices. Our study was aided by the
recent definition of the X-ray crystal structure of Bcl-2–navitoclax
(PDB ID: 4LVT) [10]. Navitoclax engages the two hydrophobic
‘hot spots’ regions termed P2 and P4 that are known to show a
high-affinity binding by proapoptotic peptides [26,27]. All docking
calculations were performed using Accelrys Discovery Studio
Version 2.5 and the automated docking program CDOCKER,
which utilises a molecular dynamics-based simulated annealing
algorithm. The active site of the enzyme was defined, and
CDOCKER docked the most active compound against the
navitoclax binding hotspot of Bcl-2. Figure 10 shows the best-
docked conformation of compound 4g and navitoclox in Bcl-2
obtained from the CDOCKER program. Docking energies of the
best configuration of compound 4g and navitoclax against Bcl-2
were 4.55 and 5.45 kcal/mol, respectively. In addition, we also
carried out the molecular docking analysis for the other bioactive
amino nitriles with Bcl-2 and its CDOCKER energies are
provided in the supplementary data (Table S2). The 3-
dimensional illustrations of the interaction map of Bcl-2 with
compound 4g, and navitoclax, were produced using the Accelrys
visualization tool (Figure 11A), and an intermolecular p-stacking
interaction of napthyl group with Phe101 and Tyr105 of P4 host
spot of Bcl-2 was observed. The 2,6-dichlorophenyl group of
compound 4g showed electrostatic interactions with the conserved
arginine (Arg104) and in turn made a unique contact with the
intra-molecular hydrogen bond formed by Ala97, Asp100,
Phe101, and Tyr199 (Figure 11A). In addition to this, the
amino-chromene scaffold was buried in the hydrophobic pocket of
Gly142, Val145, Trp141, Asn140, Phe195, Leu198, and Tyr199.
The analysis of compound 4g bound to the novitoclox binding site
showed that it shares a similar global binding motif with
navitoclax, but occupies a smaller volume within the P2 hot spot
(Figure 11B).
Conclusions
We report for the first time the solution phase, T3P-DMSO
mediated, efficient synthesis of 2-amino-chromene-3-carbonitriles
from alcohols, malanonitrile and phenols. These 2-amino-
chromene-3-carbonitriles were tested for their cytotoxicity using
human AML cell lines. Compound 4g was the most bioactive
among the structurally related compounds. It decreased prolifer-
ation, increased caspase-9 mediated apoptosis, and caused G2/M
arrest of the MOLM13, MOLM14, and MV4-11 AML cells. Our
docking analysis of 4g suggests Bcl-2 as a reasonable target, hence
rendering compound 4g as a promising Bcl-2 inhibitor for future
studies as a new anticancer agent.
Supporting Information
Table S1 Quantification of early apoptotic and late
apoptotic cells (%). AML cells were cultured with 4g (5 mM)
for either 48 or 72 hours and propidium iodide (PI) and FITC
conjugated Annexin V positive cells were enumerated. Results are
a representative experiment. The experiments were done three
times in triplicates.
(DOCX)
Table S2 Computational analysis of the binding of
amino nitriles against Bcl-2.
(DOCX)
Figure 11. Molecular docking analysis of the compound 4g in the navitoclax binding site of Bcl-2. A. The 3-dimensional orientation of
compound 4g in the navitoclax binding site of Bcl-2. Amino acid side chains are shown as stick (elements are purple color except for carbon-pink),
the inhibitor is shown as a ball and stick (elements are green color except for carbon-green). The hydrogen bonding is represented as a green dotted
line. B. Navitoclax and compound 4g bound surface view of the Bcl-2, showing the interaction at the P2 and P4 hotspot of the protein. The
electrostatic potential of the key amino acids is shown. The bound ball and stick version of the compound 4g and navitoclax are represented.
doi:10.1371/journal.pone.0107118.g011
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Data S1 General procedure for one pot synthesis of 2-
amino chromene-3-carbonitriles.
(DOCX)
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